Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
Abstract We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce derma...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.736 |